肿瘤防治研究2017，Vol.44Issue(7)：489-492,4.DOI:10.3971/j.issn.1000-8578.2017.17.0077
mFOLFOX6和FOLFIRI方案分别一线和二线治疗晚期胃癌疗效对比观察
Comparison of Clinical Effect Between mFOLFOX6 and FOLFIRI Regimen as Alternately First-and Second-line Therapy on Advanced Gastric Cancer Patients
摘要
Abstract
Objective To observe and compare the efficacy and adverse reactions between mFOLFOX6 and FOLFIRI regimen as alternately first-and second-line chemotherapy on the patients with advanced gastric cancer(AGC).Methods A total of 62 AGC patients were divided into two groups:Control group,n=32,mFOLFOX6 regimen as the first-line treatment,FOLFIRI regimen as the second-line treatment on 25 patients after disease progression;Observation group,n=30,FOLFIRI regimen as the first-line therapy,mFOLFOX6 regimen as the second-line treatment on 25 patients after disease progression.The efficacy and adverse effects were evaluated.Results The overall response rates of first-,second-line therapy between control group and observation group were 37.5％,24.0％ and 40.0％,16.0％,respectively(P=0.801,P=0.662);the median progression-free survival were (5.0±0.25),(2.0±0.36) and (6.0±0.81),(2.0±0.27) months,respectively,with no statistically significant difference (P=0.178,P=0.803);the median overall survival were (10.0± 1.06) and (11.0 ±1.17) months in two groups(P=0.500).The most common toxicities in both groups were myelosuppression,gastrointestinal tract reaction and neurotoxicity.Control group had much higher neurotoxicity than observation group,nevertheless,the rate of diarrhea in observation group was higher than that in control group in firstline treatment.Conclusion mFOLFOX6 and FOLFIRI regimen have equal effect as alternately first-and second-line treatment on AGC patients,and both can prolong survival with low toxicity.关键词
晚期胃癌/一线治疗/二线治疗/奥沙利铂/伊立替康Key words
Advanced gastric cancer/First-line therapy/Second-line therapy/Oxaliplatin/Irinotecan分类
医药卫生引用本文复制引用
童刚领,程勃然,陈晓秋,申东兰,彭安,王树滨..mFOLFOX6和FOLFIRI方案分别一线和二线治疗晚期胃癌疗效对比观察[J].肿瘤防治研究,2017,44(7):489-492,4.基金项目
广东省自然科学基金(2016A030313381) （2016A030313381）
深圳市战略新兴产业发展专项基金(JCYJ20150529151839281) （JCYJ20150529151839281）
